Author(s):
Vignesh Selvaraj, Thiayagu Senthil, Krishnanand Anilkumar, N. Jawahar, Senthil Venkatachalam
Email(s):
senthil.v@jssuni.edu.in
DOI:
10.52711/0974-360X.2021.00881 
Address:
Vignesh Selvaraj, Thiayagu Senthil, Krishnanand Anilkumar, N. Jawahar, Senthil Venkatachalam*
Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Ooty - 643001, Tamil Nadu, India.
*Corresponding Author
Published In:
Volume - 14,
Issue - 9,
Year - 2021
ABSTRACT:
Nail psoriasis to cure would like a protracted period of treatment and relapse is common. The common Side effects of oral anti-psoriatic drugs when used for the treatment of nail Psoriasis include liver toxicity, while treatment for nail psoriasis includes monthly injection of corticosteroids into the nail folds. Topical therapy, using nail lacquer as a delivery vehicle, targets the drug to its site of action, thus, drug interactions and adverse events arising from systemic drug exposure can be avoided. The transungual drug delivery system is related to the drug delivery over the nail, which is hard because of the presence of a keratin network into the nail. So, this review mainly concentrates on drug delivery over nail by using medicated nail lacquer formulations. The drug delivery via the nail plate is done due to the association of psoriasis. Generally used medications are clobetasol, tacalcito, tazarotene, urea, calcipotriene. There are several factors such as the molecular size of the drug, hydrophilicity, and lipophilicity of diffusing molecule, nature of the vehicle, formulation effect, which affects the delivery of drugs through the nail plate. This present review also mainly focuses on the delivery of drugs using formulation in the form of the medicated-psoriatic nail lacquer.
Cite this article:
Vignesh Selvaraj, Thiayagu Senthil, Krishnanand Anilkumar, N. Jawahar, Senthil Venkatachalam. Medicated Lacquer Formulation for the Treatment of Nail Psoriasis. Research Journal of Pharmacy and Technology. 2021; 14(9):5051-8. doi: 10.52711/0974-360X.2021.00881
Cite(Electronic):
Vignesh Selvaraj, Thiayagu Senthil, Krishnanand Anilkumar, N. Jawahar, Senthil Venkatachalam. Medicated Lacquer Formulation for the Treatment of Nail Psoriasis. Research Journal of Pharmacy and Technology. 2021; 14(9):5051-8. doi: 10.52711/0974-360X.2021.00881 Available on: https://rjptonline.org/AbstractView.aspx?PID=2021-14-9-95
REFERENCE:
1. Badanthadka M, D’Souza L. Imiquimod-Induced Psoriasis Mice Model: A Promising Tool for Psoriasis Research? Research Journal of Pharmacy and Technology. 2020 Jul 28; 13(7): 3508-15.
2. Manhart R, Rich P. Nail psoriasis. Clin Exp Rheumatol. 2015 Jan 1; 33(5 Suppl 93): 7-13.
3. Papp K, Cather JC, Rosoph L, Sofen H, Langley RG, Matheson RT, Hu C, Day RM. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. The Lancet. 2012 Aug 25; 380(9843): 738-46.
4. Kavitha S. Pharmacognostical Evaluation and Standardisation of Ayurvedic Formulation Patoladi Kwatha Churna for Psoriasis. Research Journal of Pharmacy and Technology. 2020; 13(3): 1171-4.
5. D'cruz D, Joshy E, Mathew J, Nair SC. Insights to the ethiopathogenesis of human nail diseases. Research Journal of Pharmacy and Technology. 2015; 8(3): 328-34.
6. Deepak HB, Prince SE. A Systematic Review on the Role of PD-1 and its Ligands in Autoimmunity. Research Journal of Pharmacy and Technology. 2017; 10(8): 2771-6.
7. Taha MM, Al-Asady ZT. Evaluation of the Effectiveness of Antioxidants and TNF-α in Iraqi Patients with Psoriasis treated with Etanercept. Research Journal of Pharmacy and Technology.
8. Gelfand JM, Gladman DD, Mease PJ, Smith N, Margolis DJ, Nijsten T, Stern RS, Feldman SR, Rolstad T. Epidemiology of psoriatic arthritis in the population of the United States. Journal of the American Academy of Dermatology. 2005 Oct 1; 53(4): 573-e1.
9. de Vries AC, Bogaards NA, Hooft L, Velema M, Pasch M, Lebwohl M, Spuls PI. Interventions for nail psoriasis. Cochrane Database of Systematic Reviews. 2013(1).
10. Lohani B, Kumar G. Pharmaceutical Sciences.
11. Kathe K, Kathpalia H. Film forming systems for topical and transdermal drug delivery. Asian Journal of Pharmaceutical Sciences. 2017 Nov 1; 12(6): 487-97.
12. Morgan AM, Baran R, Haneke E. Anatomy of the nail unit in relation to the distal digit. Nail surgery: a text and atlas. Lippincott Williams and Wilkins, Philadelphia. 2001: 1-28.
13. Rich P, Scher RK. An atlas of diseases of the nail. CRC Press; 2003 May 28.
14. Baran R, Bristow I, Dawber RP, Haneke E, Tosti A, editors. A text atlas of nail disorders: Techniques in Investigation and Diagnosis. CRC Press; 2003 Apr 3.
15. Lohani B, Kumar G. Pharmaceutical sciences.
16. Kamrani P, Pillarisetty LS. Anatomy, Bony Pelvis and Lower Limb, Toe Nails.
17. Rich P, Scher RK. An Atlas of Diseases of the Nail. CRC Press; 2003 May 28.
18. Jiaravuthisan MM, Sasseville D, Vender RB, Murphy F, Muhn CY. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. Journal of the American Academy of Dermatology. 2007 Jul 1; 5 7(1): 1-27.
19. Hussan D, Choudhary SR, Sharma D, Bhandari V, Singh M. Transungual drug delivery-a novel approach of unique features. Indo American Journal of Pharmaceutical Research. 2013; 3(6): 4460-9.
20. Kumar TP, Raju PN. Transungual drug delivery: a promising route to treat nail disorders. Int J Pharm Sci Rev Res. 2013 Apr; 2(4): 22-33.
21. Suryavanshi KA, Basrur PR, Katedeshmukh RG. Review on Nail (Transungual) Drug Delivery System. Am. J. Pharm Tech Res. 2012; 2(5).
22. Akhtar N, Sharma H, Pathak K. Onychomycosis: potential of nail lacquers in transungual delivery of antifungals. Scientifica. 2016 Mar 30; 2016.
23. Zaias N. The nail in health and disease. Springer Science and Business Media; 2012 Dec 6.
24. Rai S, Kamath BV, Subrahmanyam VM. Strategies for treatment of Onychomycosis. Research Journal of Pharmacy and Technology. 2018; 11(11): 5135-8.
25. D'cruz D, Joshy E, Mathew J, Nair SC. Insights to the ethiopathogenesis of human nail diseases. Research Journal of Pharmacy and Technology. 2015; 8(3): 328-34.
26. Pittrof F, Gerhards J, Erni W, Klecak G. Loceryl® nail lacquer—realization of a new galenical approach to onychomycosis therapy. Clinical and Experimental Dermatology. 1992 Sep; 17: 26-8.
27. Saner MV, Kulkarni AD, Pardeshi CV. Insights into drug delivery across the nail plate barrier. Journal of Drug Targeting. 2014 Nov 1; 22(9): 769-89.
28. Murdan S, Hinsu D, Guimier M. A few aspects of transonychial water loss (TOWL): inter-individual, and intra-individual inter-finger, inter-hand and inter-day variabilities, and the influence of nail plate hydration, filing and varnish. European Journal of Pharmaceutics and Biopharmaceutics. 2008 Oct 1; 70(2): 684-9.
29. Hao J, Smith KA, Li SK. Chemical method to enhance transungual transport and iontophoresis efficiency. International Journal of Pharmaceutics. 2008 Jun 5; 357(1-2): 61-9.
30. Chesnoy S, Delaunois M, Coubetergues H, Lefrancois P, inventors; Pierre Fabre Dermo Cosmetique SA, assignee. Urea-based film-forming solution for treating nail psoriasis. United States Patent Application US 13/124, 796. 2011 Aug 18.
31. Cantoresi F, Sorgi P, Arcese A, Bidoli A, Bruni F, Carnevale C, Calvieri S. Improvement of psoriatic onychodystrophy by a water‐soluble nail lacquer. Journal of the European Academy of Dermatology and Venereology. 2009 Jul; 23(7): 832-4.
32. Nakamura RC, Abreu LD, Duque-Estrada B, Tamler C, Leverone AP. Comparison of nail lacquer clobetasol efficacy at 0, 05%, 1% and 8% in nail psoriasis treatment: prospective, controlled and randomized pilot study. Anais Brasileiros de Dermatologia. 2012 Apr; 87(2): 203-11.
33. Cantoresi F, Caserini M, Bidoli A, Maggio F, Marino R, Carnevale C, Sorgi P, Palmieri R. Randomized controlled trial of a water-soluble nail lacquer based on hydroxypropyl-chitosan (HPCH), in the management of nail psoriasis. Clinical, Cosmetic and Investigational Dermatology. 2014; 7: 185.
34. Kushwaha AS, Repka MA, Murthy SN. A novel apremilast nail lacquer formulation for the treatment of nail psoriasis. AAPS Pharmscitech. 2017 Nov 1; 18(8): 2949-56.
35. Sánchez Regaña M, Martín Ezquerra G, Umbert Millet P, Lambic Mateos F. Treatment of nail psoriasis with 8% clobetasol nail lacquer: positive experience in 10 patients. Journal of the European Academy of Dermatology and Venereology. 2005 Sep; 19(5): 573-7.
36. Nakamura RC, Abreu LD, Duque-Estrada B, Tamler C, Leverone AP. Comparison of nail lacquer clobetasol efficacy at 0,05%, 1% and 8% in nail psoriasis treatment: prospective, controlled and randomized pilot study. Anais Brasileiros de Dermatologia. 2012 Apr; 87(2): 203-11.
37. Khan AD, Giri A, Singh L. Transungual drug delivery: a newer approach. World Journal of Pharmacy and Pharmaceutical Sciences. 2014 Feb 8; 3(3): 781-94.
38. Kumar K, Fateh V, Ahmad S, Pant NC, Pandey S. Drug delivery across human nail: A newer approach. International Journal of Research and Development in Pharmacy and Life Science. 2014 Nov 3; 6: 1217-22.
39. Sanchez Regana M, Márquez Balbás G, Umbert Millet P. Nail psoriasis: a combined treatment with 8% clobetasol nail lacquer and tacalcitol ointment. Journal of the European Academy of Dermatology and Venereology. 2008 Aug; 22(8): 963-9.
40. Rai S, Kamath BV, Subrahmanyam VM. Strategies for treatment of Onychomycosis. Research Journal of Pharmacy and Technology. 2018; 11(11): 5135-8.
41. Tamboli FA, More HN. In vitro antipsoriatic study of successive solvent extracts of Barleria gibsoni Dalz. using HaCa T keratinocyte cells. Research Journal of Pharmacy and Technology. 2015; 8(11): 1566-9.
42. Thatai P, Khan AB. Management of nail psoriasis by topical drug delivery: a pharmaceutical perspective. International Journal of Dermatology. 2020 Apr 2.
43. Zhang J, Warner KS, Kumar P, Aliyar H, inventors; ZARS Pharma Inc, assignee. Systems, methods, and formulations for topically treating nail fungal infections and nail psoriasis. United States Patent Application US 12/349, 922. 2009 Jul 9.
44. Kathe K, Kathpalia H. Film forming systems for topical and transdermal drug delivery. Asian Journal of Pharmaceutical Sciences. 2017 Nov 1; 12(6): 487-97.
45. Yin-Ku LI, inventor; Galderma Research, Development SNC, assignee. Oil-extracted product of indigo naturalis, and preparation process and uses thereof. United States Patent US 8, 784, 905. 2014 Jul 22.
46. Vakirlis E, Kastanis A, Ioannides D. Calcipotriol/betamethasone dipropionate in the treatment of psoriasis vulgaris. Therapeutics and Clinical Risk Management. 2008 Feb; 4(1): 141.
47. Thatai P, Khan AB. Management of nail psoriasis by topical drug delivery: a pharmaceutical perspective. International Journal of Dermatology. 2020 Apr 2.
48. Firoz S, Sirisha MN, Rajalakshmi R. Transungual drug delivery system: a review. Int J Innov Drug Disc. 2011; 1: 9-14.
49. Joshi M, Sharma V, Pathak K. Matrix based system of isotretinoin as nail lacquer to enhance transungal delivery across human nail plate. International Journal of Pharmaceutics. 2015 Jan 15; 478(1): 268-77.
50. Mohorčič M, Torkar A, Friedrich J, Kristl J, Murad S. An investigation into keratinolytic enzymes to enhance ungual drug delivery. International Journal of Pharmaceutics. 2007 Mar 6; 332(1-2): 196-201.